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MicrobiomeHumans are colonized after birth by microbial organisms that form a heterogeneous community,
collectively termed microbiota. The genomic pool of this macro-community is named microbiome.
The gut microbiota is essential for the complete development of the immune system, representing a
binary network in which the microbiota interact with the host providing important immune and
physiologic function and conversely the bacteria protect themselves from host immune defense.
Alterations in the balance of the gut microbiome due to a combination of environmental and
genetic factors can now be associated with detrimental or protective effects in experimental auto-
immune diseases. These gut microbiome alterations can unbalance the gastrointestinal immune
responses and inﬂuence distal effector sites leading to CNS disease including both demyelination
and affective disorders. The current range of risk factors for MS includes genetic makeup and envi-
ronmental elements. Of interest to this review is the consistency between this range of MS risk fac-
tors and the gut microbiome. We postulate that the gut microbiome serves as the niche where
different MS risk factors merge, thereby inﬂuencing the disease process.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction – multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disease that affects
the central nervous system (CNS). In MS, a chronic immune-med-
iated disease, auto-reactive cells attack the CNS tissue. The speciﬁc
CNS target molecules are yet to be described. Current genetic infor-
mation suggests that the critical molecules involved in disease
pathogenesis are immunologic, although whether the primary trig-
gering stage is an inﬂammatory and autoimmune or neurological
remains to be elucidated. However, it is evident that MS is charac-
terized by the inﬁltration of inﬂammatory cells to the CNS, demy-
elination, and axonal damage [1]. Lesions appear as demyelinating
plaques in both the white and gray matter of the brain and the
spinal cord. The most common symptoms of MS are consistent
with both gray and white matter disease including fatigue, numb-
ness, coordination worseness, vertigo, bladder, bowel and sexual
dysfunction, vision reduction, dizziness, pain, emotional stress
and depression [2]. Clinically MS is characterized by either relaps-
ing/remitting or a progressive condition [3].The disease is most commonly diagnosed at ages 20–50. Inter-
estingly, since the time of its ﬁrst description by the French neurol-
ogist Charcot in the late 1800’s the female/male ratio has shifted
from 1:1 to its current incidence in which it exceeds 3:1 female
tomale [4]. This differential gender ratio has arisen the last decades
with an apparent differential change, depending on the geographi-
cal location [5]. This difference in female/male MS susceptibility is
common in other, but not all, autoimmune diseases, such as Sjo-
gren’s syndrome, systemic lupus erythematosus (SLE), scleroderma,
and rheumatoid arthritis (RA) [6]. The endocrine system might be
responsible for the differences in the susceptibility female/male
ratio; however, genetic and immunological factors are no doubt
part of this complex interaction between the neuronal and immune
system. In this article, both consistent and conﬂicting hypothesis
that aim to explain the genetic and or environmental source for this
devastating disease will be reviewed. Moreover, we will postulate
the importance of themicrobial populations that inhabit the gastro-
intestinal tract as an ecosystem where multiple disease risk factors
merge. We hypothesize that the gut microbiome is an adaptable
‘‘acquired’’ immune organ that can modulate the severity MS dis-
ease. We speculate with the possible role of speciﬁc gut microbes
and more importantly speciﬁc antigen(s) derived from commensal
microbiota as both effectors and regulators of CNS demyelination
and perhaps affective disorders as well.
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with CNS demyelinating disease
Environmental, genetic, immunological and infectious diseases
have been associated with MS [2]. The genetic background is
thought to be a critical epidemiologic risk factor. As reviewed by
Compton and colleagues, the familial recurrence rate in MS is
20% [7]. Monozygotic twins, sharing the 100% of the genetic infor-
mation, have an MS lifetime risk of approximately 25–30%, siblings
with two affected parents approximately a 20%, whereas dizygotic
twins have a 5% lifetime risk, frequencies that suggest that the
genetic background could interact with other risk factors.
2.1. Genetic susceptibility and genetic risk factors
Alterations in immuno-regulatory or structural genes might
increase the susceptibility to MS. Differences in the human leuko-
cyte antigen (HLA) system—genes in the chromosome 6 that serve
as the major histocompatibility complex (MHC) in humans—haplo-
types DRBl*1501 and DQ6 have been suggested as genetic risk fac-
tors [8]. Recent genome-wide association studies (GWAS) reveal an
evident effect of these genetic risk factors, with particular impor-
tance of HLA class II region, but also class I [9,10]. Interestingly,
the genetic factors associated with MS are involved in immunolog-
ical processes [11], providing strong theoretical support to the
autoimmune nature of MS, and moreover, provides the potential
framework that environmental factors may be intimately involved
in the modulation and/or perhaps even the trigger for disease
susceptibility.2.2. Genetic, hormones and sex differences in multiple sclerosis
The incidence of a number of autoimmune diseases is higher in
women than men. Genetic factors deﬁne hormonal differences
between females and males. Also, the effect of X-chromosome
linked mutations has been suggested to affect autoimmune pro-
cesses [6]. However, genetic factors might not be sufﬁcient to
explain the documented rise in the female/male ratio observed in
the last decades. In the CNS, immune cells regulate inﬂammatory
processes, but other brain-derived modulatory factors also play a
role, by the production of cytokines and hormones, in processes
mediated by the autonomic neuronal system. Receptors expressed
in immune cells sense cytokines and hormones allowing a critical
interaction between the immune, neuronal, and endocrine system.
Multiple immune functions such as activation, proliferation, che-
motaxis, phagocytic activity and cytotoxic functions are regulated
by different endocrine pathways that take place within the CNS.
In women with MS, an increased risk factor is conferred when
DRB1*1501 is combined with the estrogen receptor alpha-4
(ERa4) polymorphism [12]. Estrogens are sex hormones with
well-documented effects in the immune system [6]. Estrogen inter-
action with its receptors expressed in T cells, B cells, dendritic cells,
macrophages, monocytes, natural killer cells and others have been
shown to impact the activation and immune function of innate
and adaptive immune cells, including regulatory T (Treg) cells [6].
Estrogen administration protects mice against EAE [13] and oral
treatment with estriol reduces the number of brain active lesions
in female RRMS and SPMS patients, according to a phase I study
[14]. A phase II trial studied the effect of a combination of oral estriol
with injections of glatiramer acetate for two years, as it was recently
reported by Voskuhl and colleagues at the American Academy of
Neurology (AAN) 66th Annual Meeting [15]. Treatment with estriol
and glatiramer acetate reduced in a 47% the number of relapses after
12 months, and after 24 months the relapse rate reduction was 32%
when compared with the placebo plus glatiramer acetate. Althoughthe mechanism of action is not fully understood, in EAE estrogen
treatment promotes tolerogenic antigen presenting cells, enhances
the expression of the immuno-modulatory programmed death-
ligand 1 (PD-L1) on B cells and reduces Th17 levels while regulates
the suppressive function of Treg cells [16].
Recently, sex differences have been directly linked to changes in
the gut microbiome and to the susceptibility to autoimmune dis-
eases, such as diabetes. In non-obese diabetic (NOD) mice, gut
microbes inﬂuenced the levels of sex hormones and had a signiﬁ-
cant effect in pancreatic beta-cell destruction, insulitis and protec-
tion against Type 1 Diabetes. Authors hypothesized that the
microbiome interacts with genetic risk factors through changes
in the endocrine system [17]. Another recently published work
suggests that the microbiome determines the different autoim-
mune susceptibility between females and males [18]. We will fur-
ther discuss the effect of diet on the gut microbiota and how diet
and gut microbes modulate disease severity. It is possible to
hypothesize that the increases observed in the female/male ratios
are based on the signiﬁcant changes observed in our lifestyle,
including habits such as smoking, consumption of high-fat diets,
stress, use of antibiotics and others. More directly related to
females is the use of contraceptive methods and their undeter-
mined effect on MS susceptibility [19]. All these factors impact
the endocrine and the immune system, but also impact the micro-
bial gut ecosystem.
2.3. Environmental factors
2.3.1. Sun exposure and vitamin D deﬁciency
A main environmental factor for MS and other autoimmune-
related diseases under high scrutiny is the deﬁciency in Vitamin
D uptake and its possible association with insufﬁcient sun expo-
sure. Meta-analysis showed a signiﬁcant inverse correlation
between MS risk and UV radiation [20], and as recently reported,
vitamin D insufﬁciency has a clear association with increased dis-
ease in those on immune modulatory therapies for MS such as
interferon (IFN)-beta [21]. Experimentally, UV radiation exposure
has been shown to reduce the severity of murine EAE [22]. In this
report, the continuous treatment with UV radiation protected mice
against the disease. Interestingly, vitamin D might not be the
mechanism of protection, and direct effect of UV light in
immuno-modulatory factors such as IL-10 production and Treg cell
induction has been postulated [23].
Several of the risk genetic and environmental factors associated
with MS, such as latitude and diet, could promote vitamin D deﬁ-
ciency and affect the immune responses. Over 200 genes are associ-
ated to vitamin D function, and suppression of antibody production
and enhancement of Th2-type immune responses have been linked
to vitamin D [24]. Epidemiological studies showed that high levels
of 25-OH Vitamin D in peripheral blood correlated with a reduced
risk of MS in Caucasian women, and was indirectly associated with
high percentages of Treg cells in MS patients [24]. In northern Eur-
ope, areas suffering low UV light exposure and vitamin D deﬁciency
show an inverse correlation with the risk of MS, despite the genetic
susceptibility due to the high frequency of HLA-DRB1 associated
with these regions [25]. The inverse correlation with MS risk
described for these low sun exposure areas could represent an
example of the multifactorial nature of the risks associated with
MS. As reviewed by Simpson and colleagues [25], diet and speciﬁ-
cally vitamin D supplementation in the diet could be a critical ele-
ment to consider, as suggested by a study showing that the diet
used by the population of this Scandinavian area is far, more abun-
dant on vitamin D when compared to other European regions [26].
Because of the described mechanisms to modulate the immune
system, vitamin D may directly affect the gut microbiota
composition. Mai and collaborators ﬁrst described a link between
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gut microbiome [27]. A reduced vitamin D intake could promote
the altered immune responses, such as effects in the induction of
FoxP3+ Treg cells and reduced T cell gut homing. These immune
effects could affect directly the microbial populations of the gut,
as suggested by Ly and colleagues [28], and lead to disease. One
of the most widely studied gut symbiont, Bacteroides fragilis,
produces a polysaccharide (PSA) that, as reviewed later in further
detail, promotes the induction of gut FoxP3+ Treg cells. As reported
by Mazmanian and his group, B. fragilis derived PSA and vitamin D
interaction appears to exacerbate the induction of FoxP3+ Treg cells
and promotes enhanced protection against experimental autoim-
munity. Moreover, preliminary studies indicate that PSA can pro-
mote the production of colonic 1,25-Dihyroxyvitamin D3 (1,25D)
from the 25D precursor, also a precursor for vitamin D [29]. Given
the experimental evidence showing that 1,25D activates the induc-
tion of Treg cells [30], it is possible that a direct connection
between vitamin D and PSA Treg cells induction pathways contrib-
ute to the association between diet, vitamin D deﬁciency, the gut
microbiome, and a merged risk factor for autoimmune diseases.
2.3.2. Cigarette smoking
In 1965, a ﬁrst case-control study reported that the percentage
of cigarette smokers among MS diagnosed patients was signiﬁ-
cantly higher than control individuals [31], although a second
study showed no association [32]. More recent studies suggest this
correlation, and possibly in the transition from relapsing-remitting
MS to secondary-progressive MS forms [33]. The interactions with
other risk factors, such as vitamin D deﬁciency [34], host genetics
and viral infections [35,36] have been also suggested. Handel and
collaborators published that the combination of genetic suscepti-
bility and environmental factor such as UV light exposure and
smoking enhance the risk factor for MS in Europe [37]. Smoking
has been described as a factor that inﬂuences the gut microbiome
in humans, with an increased microbial diversity and overall com-
position changes observed in the microbiome often volunteers
after smoking cessation [38].
2.3.3. Stress
There is a body of unpublished evidence obtained from both
patients and clinicians suggesting that stress exacerbates clinical
symptoms of MS and augments the number of relapses. One prob-
lem that arises when studying stress is its deﬁnition. Nevertheless,
stress is associated with signiﬁcant changes in the autonomic ner-
vous system, the hypothalamic–pituitary–adrenal axis, and the
vascular system [39]. In EAE, induction of stress has a signiﬁcant
impact on disease severity, as reviewed by Lovera and Reza [40],
and case-control studies in humans suggest a link between stress
conditions and relapses [41] and disease indicators such as brain
lesions evaluated by MRI [42]. Because of the effects that stress
has in neuronal, hormonal and vascular systems, the mechanisms
that might link stress with altered course of MS might be multifac-
torial and associated with the immune responses. With this regard,
animal studies reported on the association of stress and disturbed
composition of the gut microbiome, by mechanisms linked to the
gut–brain axis as suggested by Cryan and colleagues [39].
2.3.4. Diet
Although results obtained in several experimental disease mod-
els suggest an association between diet and disease, there cur-
rently is limited cause-effect information on the role of diet in
human autoimmune disease. However, the potential risk of diet
in MS in association with the gut microbiome will be further dis-
cussed in this manuscript, as well as the interactions between diet
and other risk factors, such as vitamin D and its supplementation,
also previously proposed [43].2.4. Microbial infection
The involvement of microbial agents as risk factors in MS and
other autoimmune diseases has been widely discussed, and the
improvement of the sanitation conditions suggested as the reason
behind the signiﬁcant increase observed in the incidence of these
diseases over the last century. The ‘‘hygiene hypothesis’’ states
that increased vaccination practices, extended usage of antibiot-
ics, and clean environment may alter the colonization of intesti-
nal pathogenic microorganisms. These scenarios could lead to
an imbalance between inﬂammatory Thl and Th17 and anti-
inﬂammatory Th2 and regulatory cell populations, associated
with autoimmune conditions. Commensal bacteria present in
the gut, such as B. fragilis, have been recently associated to the
hygiene hypothesis, traditionally associated to parasitic infections
by helminths [44].
The role of viruses as the inducing factor in MS has been widely
hypothesized over the past few decades. Different viruses have
been suggested as infectious factors that trigger MS. Herpes sim-
plex virus, rabies, Epstein–Barr virus, corona virus, measles, canine
distemper virus, and HTLV-1 have been implicated in MS over the
past years but to date no conclusive association has yet been estab-
lished [45]. The presence of Herpes simplex virus-6 (HHV-6) or its
DNA has been reported in MS lesions and the cerebrospinal ﬂuid of
MS patients [46], without a direct association being established
[47]. Epstein–Barr virus (EBV) is a member of the herpes virus fam-
ily and along with HHV-6, the worldwide spread and one of the
most common human viruses, has also been linked to MS as a dis-
ease trigger. Interestingly, the EBV nuclear antigen shares the
sequence with the myelin basic protein (MBP), which could explain
the induction of MBP-speciﬁc encephalitogenic T cells in MS,
through a molecular mimicry mechanism [2]. Recent epidemiolog-
ical studies comparing CNS-derived antibodies against EBV versus
other neurotropic viruses in childhood and adults MS onset failed
to sufﬁciently establish that EBV is an etiologic agent of MS,
although it may regulate the susceptibility to the disease by mod-
ifying the immune responses [48].
As discussed later through this review, the multiple and various
risk factors associated with MS may suggest that more that the
combination, rather than a single etiological factor, might be
responsible for the induction of the disease. For instance, a recent
study showed that blood obtained from individuals prior their ﬁrst
clinical manifestations had reduced 25(OH)-D levels and increased
EBV reactivity [49]. EBV and high latitudes, linked to low 25(OH)-D
levels have been also associated with a functional deﬁciency of
CD8+ T cells in their response to the virus and exacerbated expan-
sion of auto-reactive B cells that are infected with EBV [50].
3. The association of the various environmental, genetic, and
microbial risk factors in CNS demyelination and the gut
microbiome
The human body maintains a physical and chemical separation
with the exterior through the skin, andmucosal surfaces of the con-
junctiva, the respiratory, gastrointestinal (GI), and the urogenital
tracts.However, anddespite their role asbarriers, theseareas consti-
tute essential locations for the interaction between us and the envi-
ronment where we live. The skin and all mucosal tissues constitute
the ecosystem for a highly heterogeneous and abundant community
of microorganisms that represent themicrobiota. The genomic pool
that constitutes this community in association with host genome is
collectively referred to as themicrobiome. First described by Joshua
Lederberg [51], themicrobiomecomprises awidely diverse commu-
nity of bacteria, archaea, fungi, protozoa and viruses. Evolutionarily,
vertebrates and their microbiome have evolved since developing a
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in water, air or land. Microbial symbiont communities are essential
for the vertebrate’s immune system development, for the appropri-
ate digestion of food and processing of nutrients such as ﬁbers, and
also to serve as combat forces against infections [52]. The microbi-
ome is heterogeneous in its composition [52], 100 times larger than
the human genome, and in terms of individual organisms, ten times
more numerous than our individual cell counts [53]. Actinobacteria,
Firmicutes, and Proteobacteriamembers dominate the skin microbi-
ota. In the oral cavityBacteroidetes, Firmicutes, and Proteobacteria are
most abundant. The urogenital tract is primarily dominated by
Firmicutes, whereas the respiratory tract shows an abundance of
Bacteroidetes and Firmicutes. The GI tract shows a predominance of
Bacteroidetes and Firmicutes. However, there are qualitative and
quantitative differences depending on the location within the GI
tract [52]. The GI tract is the most extensive site for exposure and
interaction with the microbiome and also pathogens that utilize
the mucosa as invasion and infection sites. The host’s immune
system, determined by its genome, is responsible for the control of
symbiont, pathobiont, and pathogenic microorganisms. In turn,
the microbiota modulates the environment by inﬂuencing the
normal function and development of the GI tract. Rodent germ-free
(GF) (born and raised sterile) studies showed that the monocolon-
izationwith B. fragiliswas sufﬁcient to stimulate early development
of the gut-associated lymphoid tissue (GALT), to induce normal
organogenesis in the spleen and thymus and balanced immune
development [54].
The microbiome is also heterogeneous temporally: microbes
colonize vertebrates soon after birth, and a more stabilized microb-
iome is established early in life. The gut microbiota is affected by
numerous stimuli, in particular diet, but also our own immune
and endocrine systems that can alter its composition. Recent evi-
dences show that the adult microbiome is not as stable as previ-
ously believed, and that diet can promote signiﬁcant and rapid
changes in the overall microbial abundances [55]. Moreover, diet
and geographical factors merge affecting selectively the gut
microbiome composition [56], and combined have been proposed
as risk factors in IDB [57]. The multifactorial nature of the trigger-
ing process of MS has been also experimentally linked with symbi-
ont microbes of the GI tract. The interactions of microbes with the
host have evolved into a complex balance of host genes, environ-
ment and microorganisms. TLR5 deﬁciency, which recognizes the
ﬂagella of bacteria, led to metabolic disorders such as hyperlipid-
emia, with enhanced levels of triglycerides and cholesterol, hyper-
tension, enhanced adiposity, as well as a 20% increase in the
average body weight of mice when compared to TLR5 competent
mice [58]. Another murine TLR bacterial ligand, lipopolysaccharide
(LPS), recognized by TLR4 was linked with a permanent low-level
inﬂammatory status and increases levels of serum LPS when con-
ventional mice were fed with a high-fat diet (HFD). These mice
became obese and suffered from metabolic unbalances and dis-
eases, such Type 2 Diabetes (T2D) [59].
3.1. Obesity, CNS demyelination and the gut microbiome
Evidence suggests an association between obesity, gut microbi-
ota, and the induction of Th17 responses that could relate obesity
with various autoimmune disorders. In accordance with the exper-
imental data, the worldwide increase in the incidence of obesity
and metabolic diseases such as T2D has been associated with
changes in dietary habits [60]. The direct effect of hormones in diet
and obesity may also play a role in disease severity. Adipose-
derived hormones and adipokines, cytokines produced by adipose
cells, might constitute which diet/obesity regulate the immune
system. Leptin is a hormone produced by adipose tissue, but also
by the stomach, skeletal muscles and placenta. The proportion offat mass in the tissue regulates leptin production, thatcontrols food
intake, inﬂuences the autonomic nervous system and regulates the
production of other hormones. Mice that are deﬁcient in leptin or
in the receptors for leptin are obese and suffer from severe
immune system alterations. Interestingly, leptin-deﬁcient mice
do not develop EAE [61] while neutralizing leptin in EAE mice
reduces disease severity [62]. In MS patients, high levels of leptin
are observed in active CNS lesions [63], and in sera and cerebrospi-
nal ﬂuid (CSF) [64]. Thus, the neuroendocrine system, tightly regu-
lated by nutritional factors and habits, affects signiﬁcantly the
immune system [65]. Fasting for instance, that reduces the levels
of circulating leptin, impacts proinﬂammatory responses and reg-
ulates EAE severity [66]. Other hormones of the gut–brain axis
have shown modulatory functions in autoimmunity: Neuropep-
tides, such as vasoactive intestinal peptide (VIP) and neuropeptide
Y (NPY) affect the induction of Treg cells and migration patterns of
immune cells. VIP has been shown to induce FoxP3+ Treg cells and
be protective against experimental rheumatoid arthritis [67] and
diminish the severity of murine EAE [68]. In mice, diet-induced
gut microbiome alterations promote signiﬁcant changes in the
inﬂammatory responses elicited by the adipose tissue [69]. More-
over, the connection between adipose-derived hormones and the
gut microbiome has been seen to inﬂuence the fat-gene regulation
in the CNS [70]. These effects of the gut microbiome on the neuro-
endocrine system would then be essential in the regulation of
inﬂammation and disease severity.
It is known now that the composition of the gut microbiota of
obese donors is signiﬁcantly different to that from lean individuals
[71], and that diet impacts the composition of the gut microbiome
[55]. Westernized diet increases the relative abundance of Firmi-
cutes and reduces Bacteroidetes in mice [72]. In humans, obesity
was associated with reduced bacterial diversity and reduced abun-
dance of Bacteroidetes [71]. When fed with a western diet for eight
weeks, GF mice gain signiﬁcantly less weight and fat mass than
conventional mice and are protected against diet-induced glucose
intolerance [73]. When conventional mice receive a high-fat diet
the levels of plasma free fatty acids increase. Plasma free fatty acids
enhancement during HFD consumption and obesity has been asso-
ciated with inﬂammatory syndrome and insulin resistance, exacer-
bating inﬂammation, and promoting oxidative stress by releasing
of reactive oxygen species [74]. These enhanced free fatty acid lev-
els while subjected to high-fat diets are reduced by the treatment
with antibiotics against the gut microbiome [75]. In EAE, HFD
administration exacerbates EAE severity [76] through the activa-
tion of Th17 cells whereas a caloric-restricted diet ameliorates dis-
ease [77]. Protection by the administration of caloric-restricted
diet to SJL mice was associated with enhanced plasma levels of cor-
ticosterone and adiponectin and reduced IL-6 and leptin.
The disruption in the balanced gut microbiota is termed ‘‘dysbi-
osis’’. Dysbiosis has been suggested to be responsible for intestinal
inﬂammation that is observed in patients suffering from irritable
bowel syndrome (IBS) and inﬂammatory bowel disease (IBD). In
IBS patients, the gut microbiome composition differs signiﬁcantly
from healthy individuals [78]. In IBD patients, the analysis of the
gut microbiota revealed statistically signiﬁcant differences
between the populations of Crohn’s disease patients and ulcerative
colitis patients and healthy individuals [79]. To date, no studies on
the gut microbiome of multiple sclerosis patients have been docu-
mented, however, experimental data support the importance of the
gut microbiome in the control of the severity of the disease [80].
3.2. Commensal bacteria in the effector/regulatory network in CNS
demyelination
Given the importance of diet in the modeling of the gut microb-
iome and the effect of gut microbes controlling inﬂammation, it is
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factors merge, including those directly associated with the genetics
of the host. Studies performed using germ-free (GF) animals dem-
onstrated that presence of gut symbionts is essential in the devel-
opment of the immune system. GF mice show a default Th2 biased
immune system, with a signiﬁcant reduction of lamina propria
Th17 cells [81], the main body reservoir for these cells. Mono-col-
onization of GF mice with Segmented Filamentous Bacterium (SFB) is
sufﬁcient to restore the Th17 responses in these mice [82].
By contrast, the colonization with B. fragilis rebalances the
biased immune responses in GF mice and promotes regulatory cell
subpopulations [54]. B. fragilis is a gram-negative anaerobic bacte-
rium present in the gut of most mammals, including humans. B.
fragilis produces eight different capsular polysaccharides, essential
for the survival and proliferation in this ecosystem [83]. One of
these polysaccharides, polysaccharide-A (PSA), is a zwitterionic
tetrasaccharide with varying number of repeating units per macro-
molecule that activates and induce the proliferation of CD4+ T cells
through a TLR2-mediated antigen presenting cell recognition and
MHC class II-based presentation. PSA produced by B. fragilis can
balance the Th2 biased immune responses in GF mice, and pro-
motes strong IL-10-producing T cell responses that involve Trl
cells, FoxP3+ Treg cells, and CD39+ Treg cells. The essential role of
B. fragilis and PSA in immunoregulation and control of autoimmu-
nity will de discussed in further detail.
Gut metabolites have been also proposed as essential regula-
tors in autoimmunity. Fermentation is a hallmark that deﬁnes a
gut microbe as symbiont. Microbial processing of ﬁber generates
short-chain fatty acids (SCFA), known to promote strong anti-
inﬂammatory effects in IBD models, and to exacerbate the regu-
latory function of Treg cells. One of the mechanisms described
for the anti-inﬂammatory effect of SCFA in immune cells is by
their interaction with the G-Protein coupled Receptor 43
(GPR43) [84]. Stimulation of GPR43 with SCFA promotes the
induction of colonic IL-10-producing FoxP3+ Treg cells. Treatment
of GF mice with SCFA restores the unbalanced frequency of colo-
nic Treg cell populations and their function, and promoted the
protection against colitis [85]. A fermentation product produced
by Clostridia clusters, butyrate, has been also shown to induce
colonic Treg cells and reduce the severity of experimental colitis
in mice [86]. Remarkably, preliminary studies from Weiner et al.
presented at the 2014 Joint ACTRIMS and ECTRIMS meeting sug-
gest and differential in both archaea and butyrate producing
organism abundances in the gut microbiota of MS patients versus
healthy donors [87]. Gut symbionts are essential for the host
organism’s nutrient uptake. Moreover, their processing products
are determinant in local and systemic immune-regulation. Thus,
diet, considered an environmental risk factor in MS, appears as
a central regulator of gut microbes, with known experimental
importance in CNS demyelinating inﬂammation.4. Mechanisms of regulation of central nervous system by gut
microbes
Oral tolerance has been associated with the control of experi-
mental autoimmune diseases including EAE [88]. Genetically
attenuated strains of Salmonella have been successfully used to
induce tolerance and protection in EAE and rheumatoid arthritis
models [89]. In EAE, Salmonella enterica serovar Typhimurium
expressing the CFA/I ﬁmbriae of Enterotoxigenic Escherichia coli
confers prophylactic [90] and therapeutic [91,92] protection
against EAE after a single oral dose, in a TGF-b-producing FoxP3+
Treg cells-dependent mechanism [91]. In vivo neutralization of
TGF-b ablates the protection conferred by Salmonella-CFA induced
Treg cells [92]. These ﬁndings suggest a connection between theimmune responses elicited in the gut and the immune conse-
quences that may take place within the CNS.
Different pathways of gut-brain axis in the context of CNS
inﬂammation have been proposed. The CNS releases signaling pep-
tides that modulate dietary patterns and food intake. These signals
have direct effects in biochemical and physical processes that con-
trol nutrient absorption, and regulate endocrine pathways. As
recently reviewed by Cryan and colleagues [39], the endocrine
and nutritional regulation is mediated through the autonomic ner-
vous system and the hypothalamus–pituitary adrenal axis, consti-
tuting an essential regulatory component of the brain–gut axis that
is inﬂuenced by different factors, such as stress and diet. These
mechanisms of control may inﬂuence gut microbial communities.
In turn, gut microbes modulate brain function by the release of
metabolites such as SCFA, antigens (peptidoglycan, LPS, PSA) with
immunological effects, and endocrine factors such as 5-hydroxy-
tryptamine produced by enteroendocrine cells [52]. Recent exper-
imental evidences found in mice suggest that the GI ecosystem
modulates neuronal functions through the enteric nervous system
(ENS). The ENS is essential in controlling the integrity and func-
tions of the GI. Gut symbionts such as PSA-producing B. fragilis
and Lactobacillus rhamnosus (JB-1) reach murine ENS afferent
neurons and inﬂuence their function [93].
In MS, auto-reactive cells respond to inﬂammatory stimuli and
attack the CNS causing demyelination and axonal damage. In MS
patients, there is a primary role for interleukin-17 (IL-17) and pro-
inﬂammatory Th17 cells in its pathogenesis. IL-17 expressed by
lymphocytes found in cerebrospinal ﬂuid and plaques of MS
patients was enhanced when compared to healthy individuals
[94]. The expression of IL-17 receptor (IL-17R) and IL-22 receptor
(IL-22R) in the vessels of MS lesions are enhanced when compared
to the vessels of healthy individuals [95]. Peripheral blood mono-
nuclear cells of patients with MS exacerbation have enhanced
levels of Th17 cells (CCR6+CD161+) when compared to patients
treated with interferon (IFN)-b and glatiramer acetate [96]. As ear-
lier discussed, CNS inﬂammation may be controlled by Treg cells.
Interestingly, no signiﬁcant differences in Treg cell frequencies
between MS patients and healthy individuals were found, however,
the suppressive function of Treg cells from MS patients appears
to be reduced when compared to those obtained from healthy indi-
viduals [97]. Approved MS therapeutics such as IFN-b and glatir-
amer acetate, and currently evaluated alemtuzumab potentiate
the anti-inﬂammatory function of Treg cells in EAE and MS [98,99].
Th17 cell-suppressive Treg subset expressing CD39 is disrupted
in MS patients [100]. Similar mechanism has been observed in
autoimmune hepatitis [101]. In patients suffering from autoim-
mune hepatitis, CD39+ Treg cells have enhanced expression of
CD127 and produce IFN-c and IL-17. We have recently shown that
PSA puriﬁed from B. fragilis protects EAE mice through a CD39-
based mechanism [102]. Upon oral administration of PSA CD39+
Treg cells express higher levels of migratory signaling molecules
and accumulate within the CNS of EAE mice [103]. We now have
evidence that PSA also enhances the frequency of CD39 in human
Treg cells [104].
Numerous publications have focused on the role of B cells in MS
pathogenesis [105]. CD20+ B cells have been targeted with MS
therapeutics showing promising effect in reducing relapse rates
and lesions in RR-MS patients [106]. However, the need for the
depletion of B cells remains controversial due to the existence of
B cell subpopulations with regulatory phenotypes that are involved
in the protection to EAE. B cell-deﬁcient C57BL/6 mice suffer an
exacerbated EAE form [107] and IL-10-producing B cells trans-
ferred into IL-10 deﬁcient mice protect them against the disease
[108]. Splenic CDldhighCD5+ B cells that produce IL-10 are protec-
tive in EAE through TLR2/4 and MyD88 signaling pathway, impli-
cating a potential role for bacterial antigens in the EAE regulation
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linked to B cells. CD20 treatment attenuates diet-induced diabetes
in mice [110], and B cells isolated from obese mice and T2D
humans have a proinﬂammatory cytokine pattern, and are defec-
tive in the production of interleukin-10 (IL-10). By contrast, B
cell-null mice are protected from pathogenic outcomes of obesity
and inﬂammation [111]. In this work, DeFuria and colleges showed
that the effect of B cells in diet-induced diabetes is mediated
through their proinﬂammatory proﬁle of cytokines released and
also by potentiating the autoreactive proinﬂammatory effect of T
cells. The connection between the administration of HFD, the
induction of autoimmunity and gut microbes may relay on the
effect of the gut microbiome in B cell functions. In the murine
gut, B cells undergo development inﬂuenced by the microbiome
[112], and we have shown that alterations of the gut microbiome
modulate B cell function in EAE [113]. The adoptive transfer of
CDld+ B cells from EAE mice treated with antibiotics transferred
protection to EAE recipient mice. Flow cytometry analysis of reci-
pient mice showed reduced Thl/Th17 proﬁle after the transfer of
B cells, suggesting a secondary effect of B cells in modulating T cell
responses as observed in diabetes experimental models [111]. The
importance of B cells in MS pathogenesis, the evidences suggesting
that different phenotypes might be beneﬁcial or detrimental in the
disease course, and the potential of these cells to be modulated by
diet and changes in the gut microbiome make these cells highly
targetable and a relevant focus of future studies.
4.1. Gut helminths and CNS demyelinating diseases
Early exposure to helminths could be protective against the dis-
ease [114]. Antigens from helminths induce TLR2-dependent
immunomodulatory phenotypes in cells obtained from MS
patients [115]. Large studies are currently evaluating the beneﬁcial
effect of helminths’ infection in MS patients. A study that followed
12 relapsing-remitting MS patients naturally infected with hel-
minths compared to uninfected matched controls demonstrated
remarkable disease stability [116]. Immunological read-outs
showed that peripheral blood mononuclear cells obtained from
infected MS patients produced enhanced levels of IL-10 and TGF-
b when compared to uninfected donors, whereas inﬂammatory
IL-12 and IFN-c where reduced. A pilot study showed how ﬁve
relapsing-remitting MS patients treated orally with Trichuris suis
ova (TSO) every two weeks presented reduced gadolinium-enhanc-
ing lesions after three months of treatment [117]. These numbers
increased two months after the termination of the treatment. A
Th2 switch and a regulatory cytokine pattern were observed in
serum. An association between infection with helminthes and their
effect on the established commensal microbiota has not been
investigated.
4.2. Gut bacteria and CNS demyelinating diseases
Studies performed in different EAE models in GF mice demon-
strate that the induction and severity of CNS demyelinating inﬂam-
mation depend on the presence of the gut microbiota [118,119].
Gut microbes, such as SFB, have been implicated in the induction
of potent proinﬂammatory Th17 cell responses in the gut that ulti-
mately restore the severity of EAE in GF-mice [118]. Altering gut
microbiota abundances impacts EAE severity in mice [120,121].
Oral treatment of mice with antibiotics reduced the EAE severity
by diminished pro-inﬂammatory responses and enhanced FoxP3+
Treg cells that accumulated in mesenteric and cervical lymph
nodes (LN). FoxP3+ Treg cells obtained from the cervical LN of mice
treated with antibiotics produced elevated IL-10 levels and con-
ferred protection against EAE after adoptive transfer. When mice
treated with antibiotics were injected with anti-CD25 antibodyto neutralize the effect of CD25+ T cells, a signiﬁcant increase in
the disease severity was observed. However, the disease severity
was signiﬁcantly lower than in EAE mice not subjected to the oral
administration of antibiotics but treated with anti-CD25 antibody.
These results suggested that other regulatory cell populations that
might be important in the protection observed, such as a role for
iNKT cells [121] and IL-10 producing CD19+ B cells [113].
The periodontal Porphyromonas gingivalis potentiates glial acti-
vation, enhances proinﬂammatory responses and exacerbates EAE
[122,123] whereas Lactobacillus and Biﬁdobacterium strains regu-
late EAE severity. Biﬁdobacterium animalis reduces EAE in Lewis
rats [124] and the administration of a mixture of Lactobacillus pro-
tects mice against the disease [125]. C57BL/6 mice treated prophy-
lactically with Lactobacillus paracasei and Lactobacillus plantarum
strains showed reduced EAE clinical symptoms and proinﬂamma-
tory responses, and the combination of three different strains of
L. plantarum reduced the severity in established EAE, in a mecha-
nism associated with the induction of IL-10 producing FoxP3+Treg
cells. Probiotic Pediococcus acidilactici strain R037 [126] and Lacto-
coccus lactis engineered to produce the Heat shock protein 65
(Hsp65) [127] also reduce the severity of EAE. R037 induced IL-
10-producing Trl cells whereas L. lactis-Hsp65 promoted inducible
Treg cells and Latency-associated peptide (LAP)+ CD4+ Treg cells
expressing the membrane-bound TGF-b. A clinical trial in RRMS
using probiotics associated with disease protection in EAE is cur-
rently underway (Weiner et al., personal communication).
PSA produced by B. fragilis is, to date, the only isolated symbiont
factor that can induce strong regulatory cell populations, either
FoxP3+ Treg cells [128,129], CD39+FoxP3+ Treg cells [102], or Tr-1
cells [54,130,131] and that is protective against EAE
[102,128,132]. The presence or absence of the polysaccharide
determines the protective or pathogenic outcome of B. fragilis in
EAE [133]. A strain of B. fragilis deﬁcient in the production of PSA
restores the susceptibility of EAE in mice previously treated with
antibiotics, whereas mice recolonized with the intact strain of B.
fragilis remain protected. PSA determined the cytokine proﬁle of
colonized mice and the conversion of effector CD4+ T cells into
IL-10 producing Treg cells in vitro. In mice colonized with PSA-deﬁ-
cient B. fragilis enhanced levels of systemic IL-17 and IL-6, and
reduced IL-10 production were observed when compared to mice
colonized with intact B. fragilis. Moreover, FoxP3+ Treg cells con-
verted in vitro from CD4+FoxP3 cells obtained from mice recolon-
ized with PSA-producing B. fragilis produced enhanced levels of
IL-10 and induced EAE protection after adoptive transfer. The pro-
duction of suppressive IL-10 producing FoxP3+ Treg cells by outer
membrane vesicles (OMV) released by PSA-producing B. fragilis
was also documented, in processes dependent on TLR2 signaling
and not found when OMV’s were isolated from B. fragilis deﬁcient
in the production of PSA [134].
In EAE, prophylactic and therapeutic protection in SJL/J and
C57BL/6 was achieved by the oral treatment with a highly puriﬁed
preparation of PSA [102,128,132]. PSA promoted a signiﬁcant
accumulation of CD103+ dendritic cells and FoxP3+ Treg cells in
the cervical LN of EAE mice, but not in non-EAE animals subjected
to treatment, suggesting that an inﬂammatory stimulus might be
required in order for PSA to promote an immunological shift
[133]. PSA induced an enhanced regulatory function of CD103+
dendritic cells. EAE protection by PSA was completely abrogated
in IL-10 deﬁcient mice. Recently, it has been shown that gut-
derived plasmacytoid dendritic cells (pDC) play a signiﬁcant role
in the immunomodulatory effects of PSA-producing B. fragilis
[132]. PSA recognition by dendritic cells and plasmacytoid den-
dritic cells in mice appear to be TLR2 dependent [102,135].
Recently, our laboratory has demonstrated that PSA promotes the
expansion of a CD39+ Treg population through TLR2 activation
[102]. Oral treatment with PSA promotes the acquisition of a
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expression have an exacerbated regulatory phenotype with high
levels of IL-10 produced. The role of CD39 in the protection con-
ferred by PSA was conﬁrmed when CD39 deﬁcient mice remained
unprotected to sub-optimal EAE after treatment. Moreover, PSA
promotes an enhanced migratory phenotype in CD39+ Treg cells
with elevated levels of CCR5, CCR6, and CXCR3 [103], and adhesion
molecules such as CD49b and CD29 [102]. In vitro, CD39+ Treg cells
from PSA-treated EAE mice migrated more efﬁciently towards
inﬂamed EAE CNS tissue, and a signiﬁcant accumulation of CD39+
Treg cells were observed in EAE mice treated with PSA when com-
pared to untreated EAE mice [103].
5. Conclusions
Epidemiological and experimental data suggest the interaction
of multiple risk factors associated with multiple sclerosis. The
gut microbiome is the largest ‘‘acquired immune organ’’ and could
act as the reservoir where various and widely distinct factors,
including genetic and environmental, merge. We hypothesize that
the gut microbiome is the principal risk factor for multiple sclero-
sis, and perhaps for other autoimmune diseases as well. The clini-
cal implications of recently published works support an important
and novel role for gut symbiont organism and antigen(s) in regu-
lating peripheral immune homeostasis. Accordingly, adjustment
to the gut microbiota may be a reasonable pathway by which to
control disease pathogenesis and offer an important pathway for
the treatment of multiple sclerosis and perhaps other autoimmune
conditions.
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